Simmons Comprehensive Cancer Center - Administration - Directors Office - Administration

Fingerprint Dive into the research topics where Simmons Comprehensive Cancer Center - Administration - Directors Office - Administration is active. These topic labels come from the works of this organization's members. Together they form a unique fingerprint.

  • Network Recent external collaboration on country level. Dive into details by clicking on the dots.

    Research Output

    Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

    Smyth, L. M., Piha-Paul, S. A., Won, H. H., Schram, A. M., Saura, C., Loi, S., Lu, J., Shapiro, G. I., Juric, D., Mayer, I. A., Arteaga, C. L., de la Fuente, M. I., Brufksy, A. M., Spanggaard, I., Mau-Sørensen, M., Arnedos, M., Moreno, V., Boni, V., Sohn, J., Schwartzberg, L. S. & 27 others, Gonzàlez-Farré, X., Cervantes, A., Bidard, F. C., Gorelick, A. N., Lanman, R. B., Nagy, R. J., Ulaner, G. A., Chandarlapaty, S., Jhaveri, K., Gavrila, E. I., Zimel, C., Selcuklu, S. D., Melcer, M., Samoila, A., Cai, Y., Scaltriti, M., Mann, G., Xu, F., Eli, L. D., Dujka, M., Lalani, A. S., Bryce, R., Baselga, J., Taylor, B. S., Solit, D. B., Meric-Bernstam, F. & Hyman, D. M., Feb 1 2020, In : Cancer discovery. 10, 2, p. 198-213 16 p.

    Research output: Contribution to journalArticle

    Open Access
  • 3 Scopus citations

    Erratum: Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers (Cancer Cell (2020) 37(2) (183–199.e5), (S1535610819305835), (10.1016/j.ccell.2019.12.013))

    Sudhan, D. R., Guerrero-Zotano, A., Won, H., Ericsson, P. G., Servetto, A., Huerta-Rosario, M., Ye, D., Lee, K. M., Formisano, L., Guo, Y., Liu, Q., Kinch, L. N., Brewer, M. R., Dugger, T., Koch, J., Wick, M. J., Cutler, R. E., Lalani, A. S., Bryce, R., Auerbach, A. & 2 others, Hanker, A. B. & Arteaga, C. L., Feb 10 2020, In : Cancer Cell. 37, 2, p. 258-259 2 p.

    Research output: Contribution to journalComment/debate

    Open Access
  • Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers

    Sudhan, D. R., Guerrero-Zotano, A., Won, H., González Ericsson, P., Servetto, A., Huerta-Rosario, M., Ye, D., Lee, K. M., Formisano, L., Guo, Y., Liu, Q., Kinch, L. N., Red Brewer, M., Dugger, T., Koch, J., Wick, M. J., Cutler, R. E., Lalani, A. S., Bryce, R., Auerbach, A. & 2 others, Hanker, A. B. & Arteaga, C. L., Feb 10 2020, In : Cancer Cell. 37, 2, p. 183-199.e5

    Research output: Contribution to journalArticle